Why Is ARCA Biopharma (ABIO) Stock Up 85% Today?

Clinical-stage biopharmaceutical firm ARCA Biopharma (NASDAQ:ABIO) — which develops and commercializes cardiovascular disease therapies — saw its shares skyrocket during the midweek session. Earlier this morning, management announced a merger with Oruka Therapeutics, which ultimately aims to address chronic skin diseases. The large and expanding addressable market may bode well for ABIO stock, resulting in today’s big move.According to the official press release, the definitive agreement involves an all-sto ...